Immuneering doses first patient in Phase 2a of IMM-1-104; Phase 1 data shows safety and biomarker activity

Immuneering Corp

First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).
Phase 1 (N=41): no grade 4 TRAEs; only one grade 3 (reversible rash); most common grade 1/2: diarrhea 19.5%, nausea 19.5%.
At 320mg, pERK inhibition ≥90% for 2.7h; 100% of evaluable patients (N=22) showed no new RAS or MAPK pathway mutations by ctDNA.
53% of patients had ≥1 target lesion regression at 240/320mg; best individual regression -35.7% at 320mg in second-line.
Thomas J. Schall, Ph.D. appointed to Board of Directors as Class I Director effective March 11, 2024.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas J. Schall, Ph.D.

Director

IMRX · Immuneering Corp

Effective: 2024-03-11
Filed: March 14, 2024, 7:59 PM ET

On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas J. Schall, Ph.D. was appointed as Director at Immuneering Corp.

Action: appointed
Role: Director

Exact text from the filing

On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.

View on SEC.gov

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-034204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.